Translating from the rivers of Babylon to the coronary bloodstream

Journal of Clinical Investigation

Volumn 122, Issue 11, 2012, Pages 4293-4299

  Coller, Barry S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HIRULOG; INTEGRIN RECEPTOR; PRASUGREL; TICAGRELOR; TICLOPIDINE; TIROFIBAN;

ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COMPETITIVE INHIBITION; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; CORONARY ARTERY BLOOD FLOW; CORONARY STENT; DRUG ELUTING STENT; HEALTH CARE NEED; HEALTH EDUCATION; HEART INFARCTION; HEART INFARCTION SIZE; HUMAN; INHIBITION KINETICS; LIFE EXPECTANCY; MEDICAL EDUCATION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACEUTICAL CARE; PHYSICIAN; PRIORITY JOURNAL; RISK REDUCTION; SEDENTARY LIFESTYLE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOSIS; TRANSLATIONAL RESEARCH; X RAY CRYSTALLOGRAPHY;

ACADEMIC MEDICAL CENTERS; ANIMALS; CORONARY CIRCULATION; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84868613975     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI66867     Document Type: Conference Paper

References (98)

1. Coller BS. The physician-scientist, the state, and the oath: thoughts for our times. J Clin Invest. 2006;116(10):2567-2570. (Pubitemid 44511616)
2. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet. 2009;374(9696):1196-1208.
3. Lenfant C. Shattuck lecture - clinical research to clinical practice - lost in translation? N Engl J Med. 2003;349(9):868-874. (Pubitemid 37025407)
4. Hunink MG, et al. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA. 1997;277(7):535-542. (Pubitemid 27083982)
5. Wijeysundera HC, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA. 2010;303(18):1841-1847.
6. Rightmire GP. Out of Africa: modern human origins special feature: middle and later Pleistocene hominins in Africa and Southwest Asia. Proc Natl Acad Sci U S A. 2009;106(38):16046-16050.
7. Schroeder SA, Zones JS, Showstack JA. Academic medicine as a public trust. JAMA. 1989;262(6):803-812. (Pubitemid 19189005)
8. Wartman SA. Commentary: Academic health centers: the compelling need for recalibration. Acad Med. 2010;85(12):1821-1822.
9. Weed DL, McKeown RE. Science and social responsibility in public health. Environ Health Perspect. 2003;111(14):1804-1808. (Pubitemid 37407944)
10. Jacobson N. Dignity and health: a review. Soc Sci Med. 2007;64(2):292-302. (Pubitemid 44895631)
11. Waters HR, Rehwinkel JA, Burnham G. Economic evaluation of Mectizan distribution. Trop Med Int Health. 2004;9(4):A16-A25. (Pubitemid 38582241)
12. Thylefors B. The Mectizan Donation Program (MDP). Ann Trop Med Parasitol. 2008;1:39-44.
13. Zerhouni EA. Translational research: moving discovery to practice. Clin Pharmacol Ther. 2007;81(1):126-128. (Pubitemid 46050877)
14. Coller BS. Translational research: Forging a new cultural identity. Mt Sinai J Med. 2008;75(5):478-487.
15. Coller BS. Translational research and the physician scientist. In: Schafer AI, ed. The Vanishing Physician-Scientist? Ithaca, New York, USA: Cornell University Press; 2009:67-83.
16. Brownlee C. Biography of Barry S. Coller. Proc Natl Acad Sci U S A. 2004;101(36):13111-13113.
17. Coller BS, French DL, Rao AK. Hereditary qualitative platelet disorders. In: Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Prchal JT, eds. Williams Hematology. 8th ed. New York, New York, USA: McGraw-Hill; 2010:1735-1814.
18. Coller BS, Seligsohn U, Peretz H, Newman PJ. Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol. 1994;31(4):301-311. (Pubitemid 24325182)
19. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood. 2008;112(8):3011-3025.
20. Coller BS. Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia. Blood. 1980;55(2):169-178. (Pubitemid 10161187)
21. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983;72(1):325-338. (Pubitemid 13025874)
22. Coller BS, Seligsohn U, Zivelin A, Zwang E, Lusky A, Modan M. Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann's thrombasthenia in Iraqi-Jewish and Arab populations of Israel: Comparison of techniques for carrier detection. Br J Haematol. 1986;62(4):723-735. (Pubitemid 16129170)
23. Coller BS, Seligsohn U, Little PA. Type I Glanzmann thrombasthenia patients from the Iraqi-Jewish and Arab populations in Israel can be differentiated by platelet glycoprotein IIIa immunoblot analysis. Blood. 1987;69(6):1696-1703. (Pubitemid 17091628)
24. Seligsohn U, Mibashan RS, Rodeck CH, Nicolaides KH, Millar DS, Coller BS. Prevention program of type I Glanzmann thrombasthenia in Israel: prenatal diagnosis. Curr Stud Hematol Blood Transfus. 1988;(55):174-179. (Pubitemid 18086217)
25. Seligsohn U, Coller BS, Zivelin A, Plow EF, Ginsberg MH. Immunoblot analysis of platelet GPIIb in patients with Glanzmann thrombasthenia in Israel. Br J Haematol. 1989;72(3):415-423. (Pubitemid 19180053)
26. Newman PJ, Seligsohn U, Lyman S, Coller BS. The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci U S A. 1991;88(8):3160-3164. (Pubitemid 21916579)
27. Peretz H, Seligsohn U, Zwang E, Coller BS, Newman PJ. Detection of the Glanzmann's thrombasthenia mutations in Arab and Iraqi-Jewish patients by polymerase chain reaction and restriction analysis of blood or urine samples. Thromb Haemost. 1991;66(4):500-504.
28. Coller BS, Seligsohn U, West SM, Scudder LE, Norton KJ. Platelet fibrinogen and vitronectin in Glanzmann thrombasthenia: evidence consistent with specific roles for glycoprotein IIb/IIIA and αVβ3 integrins in platelet protein trafficking. Blood. 1991;78(10):2603-2610.
29. French DL, Coller BS, Berkowitz R, Eng C, Seligsohn U, Peretz H. Prenatal diagnosis of Glanzmann thrombasthenia using the polymorphic markers BRCA 1 and THRA 1 on chromosome 17. Br J Haematol. 1998;102(2):582-587. (Pubitemid 28346604)
30. Rosenberg N, et al. A 13-bp deletion in alpha(IIb) gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia. J Thromb Haemost. 2005;3(12):2764-2772. (Pubitemid 41819806)
31. Seligsohn U, Mibashan RS, Rodeck CH, Nicolaides KH, Millar DS, Coller BS. Prenatal diagnosis of Glanzmann's thrombasthenia. Lancet. 1985;2(8469-8470): 1419. (Pubitemid 16138566)
32. Xiao T, Takagi J, Coller BS, Wang J, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature. 2004;432(7013):59-67. (Pubitemid 39490825)
33. Coller BS, Lang D, Scudder LE. Rapid and simple platelet function assay to assess GPIIb/IIIa receptor blockade. Circulation. 9997;95(4):860-867.
34. Smith JW, et al. Rapid platelet-function assay (RPFA): an automated and quantitative cartridge-based method. Circulation. 1999;99(5):620-625. (Pubitemid 29077360)
35. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol. 2009;103(3 suppl):20A-26A.
36. Brar SS, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol. 2011;58(19):1945-1954.
37. Yamaguchi Y, Abe T, Sato Y, Matsubara Y, Moriki T, Murata M. Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: A systematic review and meta-analysis [published online ahead of print July 3, 3012]. Platelets. doi:10.3109/09537104. 2012.700969.
38. Roger VL, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-e220.
39. [No authors listed]. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed). 1988;396(6618):320- 331.
40. Coller BS. Historical perspective and future directions in platelet research. J Thromb Haemost. 2011;1(2):374-395.
41. Podesta M. Contribution a l'etude pharmacologique de thienopyridines et d'analogues furanniques. Eur J Med Chem. 1974;9:487-490.
42. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):234S-264S. (Pubitemid 39297956)
43. Hollopeter G, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409(6817):202-207. (Pubitemid 32144286)
44. Jin RC, Voetsch B, Loscalzo J. Endogenous mechanisms of inhibition of platelet function. Microcirculation. 2005;12(3):247-258. (Pubitemid 40691822)
45. Andrews RK, Shen Y, Gardiner EE, Dong J, Lopez JA, Berndt MC. The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. Thromb Haemost. 1999;82(2):357-364.
46. Ruggeri ZM. Von Willebrand factor: looking back and looking forward. Thromb Haemost. 2007;98(1):55-62. (Pubitemid 47078779)
47. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. 2008;28(3):403-412.
48. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3(8):1800-1814. (Pubitemid 41716567)
49. Smyth SS, et al. Platelet functions beyond hemostasis. J Thromb Haemost. 2009;7(11):1759-1766.
50. Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985;53(4):363-373. (Pubitemid 15055510)
51. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol. 1989;63(10):114E-120E. (Pubitemid 19074335)
52. Farb A, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation. 1996;93(7):1354-1363. (Pubitemid 26099346)
53. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature. 1984;309(5963):30-33. (Pubitemid 14134132)
54. Gold HK, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal anti-platelet GPIIb/IIIa antibody in a dog model. Circulation. 1988;77(3):670-677. (Pubitemid 18073359)
55. Yasuda T, et al. Monoclonal antibody against the platelet GPIIb/IIIa receptor prevents coronary artery reocclusion following reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest. 1988;81(4):1284-1291.
56. Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood. 1986;68(3):783-786. (Pubitemid 16008187)
57. Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: Correlation with bleeding time, platelet aggregation and blockade of GPIIb/IIIa receptors. Circulation. 1989;80(6):1766-1774. (Pubitemid 20031708)
58. Lynch JJ Jr, et al. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383. J Pharmacol Exp Ther. 1995;272(1):20-32.
59. Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation. 1994;89(4):1802-1809. (Pubitemid 24114260)
60. Coller BS, et al. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci. 1991;614:193-213.
61. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation. 1995;92(9):2373-2380.
62. Knight DM, et al. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol. 1995;32(16):1271-1281. (Pubitemid 26015106)
63. [No authors listed]. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994;330(14):956-961.
64. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA. 1999;281(9):806-810. (Pubitemid 29113740)
65. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997;80(4A):11B-20B. (Pubitemid 27369147)
66. Barrett JS, et al. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther. 1994;56(4):377-388. (Pubitemid 24339084)
67. Bosch X, Marrugat J, Sanchis J. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. Cochrane Database Syst Rev. 2010;8(9):CD002130.
68. Michelson AD. Advances in antiplatelet therapy. Hematology Am Soc Hematol Educ Program. 2011;2011:62-69.
69. Van De Car DA, Rao SV, Ohman EM. Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther. 2010;8(12):1673-1681.
70. De LG, et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med. 2012;172(8):611-621.
71. Mehran R, et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv. 2011;4(6):654-664.
72. Mamas MA, et al. Influence of access site selection on PCI-related adverse events in patients with STEMI: meta-analysis of randomised controlled trials. Heart. 2012;98(4):303-311.
73. Stone GW, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012;307(17):1817-1826.
74. DeLuca LG, Verdoia M, Suryapranata H. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: A meta-analysis of 8 randomized trials. Atherosclerosis. 2012;222(2):426-433.
75. Tang L, Zhou SH, Hu XQ, Fang ZF, Shen XQ. Effect of delayed vs immediate stent implantation on myocardial perfusion and cardiac function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention with thrombus aspiration. Can J Cardiol. 2011;27(5):541-547.
76. Jolicoeur EM, Tanguay JF. From primary to secondary percutaneous coronary intervention: the emerging concept of early mechanical reperfusion with delayed facilitated stenting-when earlier may not be better. Can J Cardiol. 2011;27(5):529-533.
77. Cuisset T, et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv. 2008;1(6):649-653.
78. Sibbing D, et al. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients: ISAR-REACT-4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. J Am Coll Cardiol. 2012;60(5):369-377.
79. Marcos EG, Da Fonseca AC, Hofma SH. Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation. Neth Heart J. 2011;19(10):412-417.
80. Aggour M, Pierot L, Kadziolka K, Gomis P, Graftieaux JP. Abciximab treatment modalities for thromboembolic events related to aneurysm coiling. Neurosurgery. 2010;67(2 suppl operative):503-508.
81. Hassan AK, et al. Incidence, patient characteristics and predictors of aborted myocardial infarction in patients undergoing primary PCI: prospective study comparing pre- and in-hospital abciximab pretreatment. EuroIntervention. 2009;4(5):662-668.
82. Dudas K, Lappas G, Stewart S, Rosengren A. Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). Circulation. 2011;123(1):46-52.
83. Roger VL, et al. Executive summary: heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188-197.
84. Gold HK, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activa- tors: observations in animals and man. Circulation. 1997;95(7):1755-1759. (Pubitemid 27164388)
85. Hassan AK, et al. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program. Catheter Cardiovasc Interv. 2009;74(2):335-343.
86. DeLuca LG, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J Thromb Haemost. 2011;9(12):2361-2370.
87. Ohlmann P, et al. Prehospital abciximab in ST-segment elevation myocardial infarction: results of the randomized, double-blind MISTRAL study. Circ Cardiovasc Interv. 2012;5(1):69-76, S1.
88. Chew DP, Bhatt DL, Topol EJ. Oral glycoprotein IIb/IIIa inhibitors: why don't they work? Am J Cardiovasc Drugs. 2001;1(6):421-428.
89. Cox D. Oral GPIIb/IIIa antagonists: what went wrong? Curr Pharm Des. 2004;10(14):1587-1596. (Pubitemid 38559770)
90. Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest. 2005;127(2 suppl):53S-59S. (Pubitemid 40224082)
91. Bednar B, et al. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood. 1999;94(2):587-599. (Pubitemid 29323873)
92. Blue R, Murcia M, Karan C, Jirouskova M, Coller BS. Application of high throughput screening to identify a novel ?IIb-specific small molecule inhibitor of ?IIb?3-mediated platelet interaction with fibrinogen. Blood. 2008;111(3):1248-1256. (Pubitemid 351213407)
93. Blue R, et al. Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel αIIb-specific αIIbß3 antagonist. Blood. 2009;114(1):195-201.
94. Zhu J, Negri A, Provasi D, Filizola M, Coller BS, Springer TA. Closed headpiece of integrin αIIbß3 and its complex with an αIIbß3-specific antagonist that does not induce opening. Blood. 2010;116(23):5050-5059.
95. 2+ binding to the MIDAS. Sci Transl Med. 2012;4(125):125ra32.
96. Hantgan RR, Stahle MC, Connor JH, Connor RF, Mousa SA. AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists. J Thromb Haemost. 2007;5(3):542-550. (Pubitemid 46680688)
97. Hantgan RR, Stahle MC. Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3:PAC-1 molecular recognition. Biochemistry. 2009;48(35):8355-8365.
98. Du XP, et al. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell. 1991;65(3):409-416.